MARKET WIREReuters • 50m ago
COMMENTARY: Asia's crude oil imports back to pre-war levels but refined fuels lag - ReutersCOMMENTARY: Asia's crude oil imports back to pre-war levels but refined fuels lag Reuters
Why VANI Stock Traded Steady Today — RQD Quant Desk Flash
$1.14 0.00% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $1.14
Vivani Medical Inc. (VANI) carries a Roarable Rating of E (Strong Sell) with 34/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE E • RED ALERT
Cap $102.8M
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on VANI Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is VANI stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-01, Vivani Medical Inc. (NASDAQ: VANI) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 34/100 at a spot price of $1.14 (0.00% 1D, market cap $102.8M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 7/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, VANI ranks #844 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does VANI compare to NRXS and STXS in the Health Care sector?
▼
Within the Health Care sector (Biotechnology: Electromedical & Electrotherapeutic Apparatus), VANI carries a Roarable E (34/100 RQD), trailing P/E of 3.9x, gross margin of —, and ROIC of -35.0%. By comparison, NRXS (Neuraxis Inc.) holds a E grade (32/100 RQD, P/E N/A, ROIC -35.0%, cap $94.8M) and STXS (Stereotaxis Inc.) posts a E grade (30/100 RQD, P/E N/A, ROIC -35.0%, cap $91.2M). Among the 5-stock peer group, VANI leads on earnings multiple (3.9x) while OM leads on capital efficiency (-28.0% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for VANI?
▼
Per VANI's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001266806), Vivani Medical Inc. generated $0 in revenue, $26.6M in net income, and -$25.5M in free cash flow against $39.4M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $1.14 (-0.19%)🧬 Dilution Drag (+1.92% YoY Shares)⚙️ Cash Engine: 4/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (34/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-8.7% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERRED ALERT • E
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw E · Rk D
Each axis scored 0–20
12M PRICE TARGET CONE-10.5% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for VANI)Realized 20D OHLCV Swing Band: ±10%
Deterministic 5-Pillar Attribution (34/100 Composite)
🔍 WHY VANI SCORES 34/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (29% of score)
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 3/9
▲ #2 Bullish Driver: Macro Regime Fit+8/20 pts (24% of score)
FRED Regime × Technicals: 30% of 52W Range • RSI-14 at 36 (NEUTRAL RANGE)
▼ #1 Drag / Risk Factor: Cash Engine Quality4/20 pts (-16 pt drag)
Capital intensity & 0% operating margin leave 16 pts on the table
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade D$1.25-10.4% Next Q
42
Q2 (-2Q)Grade E$1.12-0.9% Next Q
39
Q3 (-1Q)Grade E$1.11+2.7% Next Q
37
CurrentGrade E$1.14-8.7% Hist 90D α
34
Trajectory: D (42) → E (34)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a VANI Turnaround Squeeze
While VANI currently carries a cautious 34/100 (E) rating due to Cash Engine Quality (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.25) and Max Pain ($1.20) forces dealer call-delta covering toward $1.74.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.92% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $VANI• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “VANI Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why VANI Stock Traded Steady Today — RQD Quant Desk Flash
Vivani Medical Inc. (VANI) slipped 0.00% to $1.14, trading at 30% of its 52-week range ($0.92 – $1.66). Stretched risk/reward at 4x P/E (-35% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 30% of its 52-week range ($0.92 – $1.66) with RSI-14 at 36 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±10% around $1.14 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable E (Strong Sell) backed by 52% gross margin and $0 annual free cash flow.
Live VANI Headlines & Catalysts
CATALYSTReuters • 3h ago
Indian shares rise on Iran war talks, Reliance earnings beat - ReutersIndian shares rise on Iran war talks, Reliance earnings beat Reuters
MARKET WIREReuters • 6h ago
Russia's FSB says minor detained over park attack threat after US tip-off - ReutersRussia's FSB says minor detained over park attack threat after US tip-off Reuters
MARKET WIREReuters • 7h ago
Oil prices ease 3% on optimism for Qatari-led talks on ending Iran war - ReutersOil prices ease 3% on optimism for Qatari-led talks on ending Iran war Reuters
MARKET WIREReuters • 8h ago
Nine people dead in Learjet crash in south Florida, officials say - ReutersNine people dead in Learjet crash in south Florida, officials say Reuters
MARKET WIREReuters • 10h ago
Iran's IRGC Navy says two tankers 'exploded' after hitting mines in Hormuz - ReutersIran's IRGC Navy says two tankers 'exploded' after hitting mines in Hormuz Reuters
MARKET WIRECNBC • 12h ago
Here are 3 big things we're watching in the stock market in the week aheadThe market could use a few victories in the days ahead, which will be filled with more earnings, an election, and jobs data.
MARKET WIRECNBC • 12h ago
Democratic Rep. Stevens endorses Rogers over El-Sayed in Michigan Senate electionHaley Stevens had lost the Democratic nomination for Senate in Michigan to Abdul El-Sayed earlier this year.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring VANI)
- ✓Walkthrough of VANI's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
VANI // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -14.93%▼ DESCENDING CHANNEL
2026-10-30O $1.12H $1.14L $1.07C $1.14VOL 198.0K
RES: $1.37SUP: $1.05SMA50: $1.25SMA200: $1.26
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
VANI Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
-15.0%/yr Implied 5Y Growth
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on VANI today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for VANI. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for VANI today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (VANI)
Health Care Rank #844 of 1016
⚔️ NRXS vs VANI Full Matrix →
1. Head-to-Head Health Care Peer Comparison (VANI vs. NRXS, STXS, HYPR, OM)
Industry: Biotechnology: Electromedical & Electrotherapeutic Apparatus (26 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Vivani Medical Inc. (VANI) ranks #844 by composite RQD confidence (34/100, grade E) and #658 by equity capitalization ($102.8M). Within this direct 5-issuer industry benchmark cohort, VANI leads on earnings valuation at 3.9x trailing P/E, while OM leads on capital efficiency and profitability with -28.0% ROIC and 39.1% gross margin. HYPR currently holds the highest overall quantitative score in the immediate peer group at 45/100 (D) compared with VANI at 34/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| VANI
ACTIVE
Vivani Medical Inc. | E | 34/100 | 3.9x | — | -35.0% | 0.00% | $102.8M | Benchmark Subject |
| NRXS Neuraxis Inc. | E | 32/100 | — | 84.2% | -35.0% | -0.26% | $94.8M | /nrxs-vs-vani → |
| STXS Stereotaxis Inc. | E | 30/100 | — | 52.7% | -35.0% | -6.21% | $91.2M | /stxs-vs-vani → |
| HYPR Hyperfine Inc. (Class A) | D | 45/100 | — | 49.8% | -35.0% | -5.23% | $78.9M | /hypr-vs-vani → |
| OM Outset Medical Inc. | D- | 35/100 | — | 39.1% | -28.0% | -3.46% | $78.8M | /om-vs-vani → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001266806In its most recent audited fiscal period (FY2025, filed 2025-12-31), Vivani Medical Inc. (VANI) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of $26.6M, operating cash flow of -$24.3M, and free cash flow of -$25.5M (-19.4% YoY). On the balance sheet, VANI closed FY2025 with $39.4M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $0 | $26.6M | -$24.3M | -$25.5M | $39.4M | — |
| FY2024 (FY) | 2024-12-31 | $0 | $23.5M | -$20.8M | -$21.3M | $41.6M | — |
| FY2023 (FY) | 2023-12-31 | $0 | $25.7M | -$23.7M | -$23.7M | — | — |
3. VANI Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs VANI stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-01, Vivani Medical Inc. (NASDAQ: VANI) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 34/100 at a spot price of $1.14 (0.00% 1D, market cap $102.8M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 7/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, VANI ranks #844 in composite RQD confidence.
How does VANI compare to NRXS and STXS in the Health Care sector?
Within the Health Care sector (Biotechnology: Electromedical & Electrotherapeutic Apparatus), VANI carries a Roarable E (34/100 RQD), trailing P/E of 3.9x, gross margin of —, and ROIC of -35.0%. By comparison, NRXS (Neuraxis Inc.) holds a E grade (32/100 RQD, P/E N/A, ROIC -35.0%, cap $94.8M) and STXS (Stereotaxis Inc.) posts a E grade (30/100 RQD, P/E N/A, ROIC -35.0%, cap $91.2M). Among the 5-stock peer group, VANI leads on earnings multiple (3.9x) while OM leads on capital efficiency (-28.0% ROIC).
What are the biggest fundamental strengths and SEC risk factors for VANI?
Per VANI's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001266806), Vivani Medical Inc. generated $0 in revenue, $26.6M in net income, and -$25.5M in free cash flow against $39.4M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is VANI trading relative to its 50-day, 200-day, and 52-week technical levels?
VANI last traded at $1.14 (0.00% on volume of 195,137 shares), positioning the stock -8.80% below its 50-day simple moving average ($1.25) and -9.52% below its 200-day simple moving average ($1.26). Across its 52-week range of $0.92 to $1.66, VANI sits at the 29.7% percentile with a 14-day RSI of 36.0 (NEUTRAL RANGE) and an implied next-earnings move of ±10.0% ($1.03 to $1.25).
VANI Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is VANI stock moving today?
Why VANI Stock Traded Steady Today — RQD Quant Desk Flash. Stretched risk/reward at 4x P/E (-35% return on capital) under elevated 10-year interest-rate pressure.